RECOMMENDED PRODUCTS
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 512194 | Lazertinib | 1903008-80-9 | 98% Min. |  |
| Description：Lazertinib is a an orally available third-generation, selective inhibi | ||||
| 185235 | Trilaciclib (G1T28) | 1374743-00-6 | >98% |  |
| TRILACICLIB (G1T28), A HIGHLY POTENT, TRANSIENT CDK 4/6 INHIBITOR WITHIC50s OF 1 nM A | ||||
| 18722 | Fezolinetant | 1629229-37-3 | >98% |  |
| Fezolinetant, also known as ESN-364, is Neurokinin-3 (NK-3) receptor antagonist which | ||||
| 187122 | Gefapixant | 1015787-98-0 | 98% |  |
| Gefapixant, also known as AF-219 or MK-7264, is a P2X3 receptor antagonist. Gefapixan | ||||
| 188281 | Arimoclomol maleate | 289893-26-1 | 98% |  |
| Arimoclomol, also known as BRX-220, is potentially useful for the treatment of Nieman | ||||
| 1810163 | BMS-986165 | 1609392-27-9 | >99% |  |
| BMS-986165 potently binds to the Tyk2 pseudokinase domain (Ki = 0.02 nM). BMS-986165 | ||||
| 1810164 | Pemigatinib (INCB054828) | 1513857-77-6 | 98% |  |
| Pemigatinib (INCB054828) is an orally active, selectiveFGFRinhibitor withIC50s of 0.4 | ||||
| 1811121 | DCC-2618 ( Ripretinib ) | 1442472-39-0 | >98% |  |
| Ripretinib, also known as DCC-2618, is a potent, orally active and selective KIT/PDGF | ||||
| 1811162 | PF-05231023 | 1037589-69-7 | >98% |  |
| PF-05231023 is a long-acting FGF21 mimetic. PF-05231023 decreases body weight and imp | ||||
| 5141902 | Avatrombopag maleate | 677007-74-8 | 96% |  |
| Avatrombopag maleate is an orally bioavailable, small molecule thrombopoietin recepto | ||||
| 1811211 | Anlotinib HCl ( AL-3818 ) | 1360460-82-7 | ≧98.0% | _1360460-82-7.png) |
| Anlotinib is a novel oral tyrosine kinase inhibitor (TKI) targeting c-kit, platelet-d | ||||
| 191146 | AR-9281 | 913548-29-5 | >98% |  |
| AR-9281 is a soluble epoxide hydrolase (s-EH) inhibitor potentially for the treatment | ||||